Rare Disease Networks: Pharma’s Key to Reducing Risk and Driving Innovation
In rare diseases, patients aren’t on the sidelines – they are central partners. Their lived experience fills critical evidence gaps and shapes what “meaningful outcomes”
In rare diseases, patients aren’t on the sidelines – they are central partners. Their lived experience fills critical evidence gaps and shapes what “meaningful outcomes” truly are. Rare Disease Networks bring together patients, clinicians, regulators, and pharma to create smarter, more feasible development pathways. We explore how and why in our latest blog, written by […]
In rare diseases, patients aren’t on the sidelines – they are central partners. Their lived experience fills critical evidence gaps and shapes what “meaningful outcomes”
At LDA Research, we know that behind every data point is a real person, a real family, and a real story. We’re sharing one of
Senior moderator Leigh Hart explores the role of pharmaceutical companies in the Rare Disease Networks, what was planned and how it has worked out. Rare
Senior Moderator Andrew Grant explores the capabilities and limitations of AI in qualitative research, sharing first hand insights from an experiment using Google Gemini to
This Chronic Disease Awareness Day patient advocate Roxanne Murray strives to ensure no one is left unseen or unheard in the MS, chronic illness and
Our senior research manager and blog contributor Rachel Barnes is celebrating working with LDA Research for a decade. Here she shares her secrets to successful
